The extracorporeal membrane oxygenation (ECMO) machine market is growing. This is mainly due to various reasons, such as the incidence of severe respiratory and cardiac failure. Moreover, the increasing adoption of advanced life-support technologies in critical care and the rising application of ECMO not only in adults but also in pediatric patients are also facilitating the growth of the ECMO machine market worldwide. ECMO machines are commonly used in intensive care units for treating ARDS (acute respiratory distress syndrome), cardiogenic shock, post-cardiotomy failure, and as a bridge to heart or lung transplantation.
ECMO regulatory and clinical guidelines are mostly influenced by national health authorities and international clinical bodies, with the aim of patient safety and standardization of use. The U.S. Food and Drug Administration (FDA) classifies ECMO machines as high-risk medical devices. Consequently, it requires manufacturers to undergo the premarket approval and post-market surveillance processes. The clinical best-practice guidelines and accreditation standards are mainly led by the Extracorporeal Life Support Organization, which issues evidence-based protocols for patient selection, management, and training of ECMO centers internationally.
In Europe, ECMO equipment must fulfill the Medical Device Regulation (MDR) criteria under the supervision of notified bodies. At the same time, the World Health Organization plays a role in overall global policy harmonization and emergency care instructions, especially during pandemics and widespread respiratory health emergencies.
However, the key challenges that continue to hinder the use of these include high expenditure on equipment and maintenance, and risks like bleeding or infection. Over the coming years, these restrictions may be reduced. For instance, rising healthcare spending in emerging economies, the proliferation of cardiac and pulmonary care centers, and the increasing survival rate due to early ECMO intervention are some factors that might drive market growth for an extended period. The ECLS Registry Report illustrates worldwide ECMO-supported patient statistics from the ELSO Registry. It displays the overall results of newborns, children, and adult patients classified by respiratory, cardiac, or ECPR treatment. Adults with Pulmonary care Survived 24 hrs were 65%, and Survived were 59% according to the 2025 report.
Thus, ECMO machines are expected to be recognized as a vital element of the advanced critical-care therapy on a global scale.
Market Drivers
Rising Incidence of Severe Respiratory and Cardiac Disorders
One of the main factors driving the extracorporeal membrane oxygenation machine market’s growth is the increasing number of cases of severe pulmonary and heart diseases. The demand for life-support systems has increased sharply due to the rising global cases of acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), severe pneumonia, heart failure, and cardiogenic shock. Heart Failure Epidemiology and Outcomes Statistics has revealed that about 6.7 million Americans over the age of 20 have heart failure in 2025, and the number of cases is anticipated to increase to 8.7 million by 2030.
As the number of elderly people increases, the number of people with lifestyle-related illnesses like hypertension and diabetes also rises. Patients who survive complex cardiac surgeries are living longer, which is leading to a larger number of critically ill patients in need of temporary heart-lung support. Extracorporeal membrane oxygenation is becoming the choice of intervention for patients whose condition worsens despite maximal mechanical ventilation or drug therapy, as it can provide oxygen and blood flow, thus stabilizing them and increasing survival rates.
Extensive clinical recommendations and registry data from the Extracorporeal Life Support Organization have endorsed ECMO's role in the treatment of severe respiratory and cardiac failure, thereby increasing hospitals’ willingness to enhance ECMO facilities. With the global increase in cardiopulmonary diseases, the demand for extracorporeal life-support technologies is likely to rise.
A primary challenge is the exorbitant total cost of care, encompassing the machine, single-use circuits, and the lengthy, high-acuity intensive care unit (ICU) stay. This constraint directly suppresses demand in budget-sensitive healthcare systems and limits accessibility, thereby impacting total procedure volume. Conversely, a significant opportunity lies in the development of portable and miniaturized ECMO systems. These advancements enhance the ability to safely transport critically ill patients, expanding the clinical application from in-ICU rescue therapy to pre-hospital or inter-hospital transfer support. This technological shift broadens the demand profile from fixed hospital units to include emergency medical services and specialized transport teams, generating a new segment of demand.
Raw Material and Pricing Analysis:
The Extracorporeal Membrane Oxygenation Machine is a physical product composed of durable hardware and single-use consumables. The key consumable components, particularly the oxygenator, rely heavily on polymer sciences, specifically polymethylpentene (PMP) for the hollow-fiber membrane, and biocompatible coatings, such as heparin, for the entire blood-contacting circuit. Price stability in the highly specialized polymer and chemical coating market is crucial, as any volatility in the cost of these medical-grade raw materials directly influences the pricing of the disposable oxygenator and cannula sets, which represent the consistent, high-volume revenue stream for manufacturers. As component innovation, such as improved thrombogenic resistance, increases, the premium pricing for these advanced disposable circuits is justified by the clinical imperative for improved patient safety and prolonged run times.
Supply Chain Analysis:
The global supply chain for ECMO systems is centralized, relying on specialized manufacturing hubs, predominantly in North America and Europe, where the dominant market players are headquartered. The primary logistical complexity stems from the need for precision manufacturing and sterilization of the disposable circuits, which are composed of multiple specialized components, including the oxygenator, centrifugal pump head, and cannulas. The system exhibits a dependency on high-purity medical-grade polymers and specialized anti-thrombotic coatings, which can introduce vulnerability to global chemical supply disruptions. The distribution model is highly regulated, necessitating rigorous temperature and environmental controls to deliver sterile, ready-to-use disposable components directly to tertiary care hospital ICUs and operating rooms.
Government Regulations:
Jurisdiction | Key Regulation / Agency | Market Impact Analysis |
United States | FDA (Food and Drug Administration) | Mandates Pre-Market Approval (PMA) or 510(k) clearance for ECMO devices. This stringent regulatory path dictates the pace of new product introduction, ensuring safety and efficacy but creating a high barrier to entry and a lengthy product development cycle, which can slow the adoption of new technologies. |
Europe | European Medicines Agency (EMA) / CE Mark | Requires adherence to the Medical Device Regulation (MDR) for market access. The focus on comprehensive clinical data and post-market surveillance provides manufacturers with a standardized, though complex, path to market, supporting competitive product launches across the EU, thereby potentially increasing demand through broader product availability. |
China | NMPA (National Medical Products Administration) | Governs the registration and approval of imported and domestically manufactured devices. The strict import registration process and emphasis on local clinical trials create a significant market barrier for international players, but simultaneously catalyze domestic manufacturing and R&D investment, fostering localized supply chains and increased demand for NMPA-approved devices. |
September 2024: Medtronic initiated the rollout of its VitalFlow ECMO one-system solution in the U.S. following its acquisition of MC3 Cardiopulmonary in March 2024. The introduction of the VitalFlow system, which includes the Medtronic Nautilus oxygenator design, directly increases the demand for their new, integrated consumables portfolio. This product launch positions Medtronic to capture a larger market share for portable and easily transportable ECMO support devices in the critical care environment.
March 2024: Medtronic announced the acquisition of MC3 Cardiopulmonary, a company specializing in advanced technologies for extracorporeal life support. This merger and acquisition event was explicitly undertaken to consolidate and expand Medtronic's cardiac surgery portfolio, immediately enhancing its capacity to deliver the next generation of integrated ECMO solutions. The acquisition strengthens Medtronic's competitive position and increases its production capacity and product range to meet the rising global demand for comprehensive ECMO systems.
By Product: ECMO Machines
By product, the extracorporeal membrane oxygenation machine market is segmented into ECMO Machines and Software. An ECMO machine is a sophisticated life-support system that provides long-term cardiac and respiratory assistance when the heart and/or lungs fail to provide adequate gas exchange and/or circulatory function. The ECMO machine removes blood from the body, adds oxygen to the bloodstream through a membrane, removes carbon dioxide from the bloodstream, and reintroduces the oxygenated blood to the person.
ECMO systems are categorised as high-risk life-sustaining medical devices, subject to stringent safety, performance, and post-market surveillance requirements. These devices are primarily used in intensive care units, the cardiothoracic surgery department, and the emergency room. The national clinical guidelines published by the National Health Commission of China classify ECMO as an important technology in critical care and provide guidelines for device design and use, including specifications for configuration, operating procedures, monitoring parameters, and facility preparedness, in accordance with national standards of care.
This figure presents the projected crude prevalence of hypertension in the United States, estimated at 36.5% in 2025 and rising to 37.3% by 2030. Hypertension is one of the most significant risk factors for severe cardiovascular complications, including heart failure, stroke, and cardiogenic shock. The sustained increase in hypertension prevalence contributes to a growing pool of high-risk patients who may require advanced life-support interventions in critical care. This directly supports the long-term demand for ECMO machines, as hypertension-related cardiac events increase the incidence of acute circulatory and respiratory failure treated using ECMO in tertiary and quaternary healthcare facilities across the United States.
By Modality Outlook: Veno-Venous (VV) ECMO
The Veno-Venous (VV) ECMO segment focuses exclusively on respiratory support, bypassing the lungs while allowing the heart to continue functioning. The core growth driver for VV ECMO is the increasing worldwide prevalence of severe, refractory ARDS, notably highlighted by the global health crisis but also driven by conditions like severe pneumonia, trauma, and inhalation injury. The clinical rationale is to apply a "lung rest" strategy, minimizing the ventilator-induced lung injury (VILI) associated with high-pressure conventional mechanical ventilation. The growing evidence from large-scale clinical trials supporting improved survival outcomes when ECMO is utilized for severe ARDS, compared to conventional management, directly fuels demand. This has prompted academic medical centers and large hospital networks to invest in dedicated ECMO centers of excellence, requiring not only the main ECMO console but a continuous supply of specialized VV cannulas and high-efficiency oxygenators optimized for gas exchange. The necessity is further concentrated in adult critical care, which accounts for the largest proportion of VV ECMO usage.
North America: the US Market Analysis
The U.S. market for the ECMO machine will continue to grow through 2025 due to the rising demand for critical care and more frequent use of advanced life-support technologies in major hospitals. The ECMO system is used in cases of severe respiratory failure and cardiac failure (e.g., acute respiratory distress syndrome (ARDS), complications after heart surgery, and complex transplant surgeries).
Federal datasets from hospitals and other clinical reporting facilities indicate that ECMO continues to be an important part of the overall infrastructure of intensive care, primarily in large academic and regional trauma hospitals. As more patients suffer from chronic respiratory disease, heart failure, and undergo high-risk surgery, the demand for extracorporeal support (ECMO) systems will continue to expand. Additionally, ECMO is also steadily used in pediatric and neonatal units for treating congenital and/or critically ill children, contributing to a growing need for ECMO machines.
ECMO aligns with the broader national goals of increasing capacity in critical care by improving survival for the most complex patients and employing advanced clinical intervention techniques.
This figure illustrates the projected crude prevalence of cardiovascular disease (CVD) in the United States, showing a prevalence of 39.7% in 2025 and is expected to 40.5% by 2030, based on national public health projections. The consistently high burden of CVD directly supports the long-term demand for ECMO machines, as severe cardiac conditions are one of the primary clinical indications for ECMO therapy. Rising CVD prevalence increases the number of patients at risk of cardiogenic shock, acute heart failure, and post-cardiac surgery complications, all of which require advanced life-support systems. This trend strengthens the strategic importance of ECMO within critical care infrastructure across U.S. hospitals.
List of Companies
Getinge AB
Medtronic plc
Fresenius Medical Care
LivaNova, plc
Terumo Corporation
Abbott Laboratories
EUROSETS S.r.l.
Senko Medical Instrument Mfg. Co., Ltd.
Nipro Corporation
Braile Biomédica
Johnson & Johnson
MicroPort Scientific Corporation
The extracorporeal membrane oxygenation machine market is influenced by well-established medical technology companies that emphasize innovation and worldwide expansion. Leading companies such as Getinge AB, Medtronic, Fresenius Medical Care, LivaNova, Inc., Terumo Corporation, Abbott, EUROSETS, Nipro Corporation, Braile Biomédica, Johnson & Johnson, and MicroPort Scientific Corporation are continuously innovating the market by offering advanced ECMO systems, oxygenators, and perfusion technologies. Competition centers on technological differentiation, particularly in biocompatibility, system portability, and integration of advanced monitoring features, alongside the cost and reliability of the disposable oxygenator and pump circuits.
Medtronic plc
Medtronic, a global leader in medical technology, maintains a strong competitive position in the ECMO market by integrating its cardiopulmonary support offerings. The company strategically leverages its extensive global distribution network and expertise in perfusion systems to drive the adoption of its ECMO portfolio. A key product is the VitalFlow ECMO system, which features a simplified, fully integrated design intended to bridge the gap between bedside care and intra-hospital transport. Medtronic strengthened this position through the acquisition of MC3 Cardiopulmonary in March 2024, aiming to offer a comprehensive, one-system ECMO solution across key markets.
LivaNova
LivaNova focuses its strategy on advanced circulatory support and cardiopulmonary products. The company's competitive edge is built on providing comprehensive systems, including the LifeSPARC System, which is intended for temporary cardiopulmonary bypass and extracorporeal life support (ECLS). The LifeSPARC system is designed around a centrifugal blood pump, aiming to provide a user-friendly and effective solution for adult patients with acute respiratory or cardiac failure. LivaNova employs a strategic focus on expanding indications for its circulatory support technology, aiming to enhance its market share through technological innovation in the cardiac and respiratory support domain.
Getinge AB
Getinge, a major player in products and systems for surgery, intensive care, and cardiovascular procedures, positions its ECMO offerings under its flagship perfusion and life support portfolio. The company's focus is on providing reliable, high-performance systems and consumables to critical care environments. Getinge's offerings, which include the Cardiohelp System, emphasize patient safety, transport capability, and ease of use in diverse clinical settings, maintaining a competitive position through a robust product range for both cardiac surgery and critical care applications.